6 results on '"Sabido R"'
Search Results
2. Overcoming resistance: virologic response to a salvage regimen with the combination of ritonavir plus indinavir.
- Author
-
Casado JL, Moreno A, Martí-Belda P, Sabido R, Pinheiro S, Bermudez E, Antela A, Dronda F, Perez-Elías MJ, and Moreno S
- Subjects
- Adult, Drug Resistance, Viral, Drug Therapy, Combination, Female, Genotype, HIV drug effects, HIV enzymology, HIV genetics, HIV Protease genetics, HIV Protease Inhibitors blood, Humans, Indinavir blood, Male, Mutation, RNA, Viral blood, Ritonavir blood, HIV Infections drug therapy, HIV Infections virology, HIV Protease Inhibitors therapeutic use, Indinavir therapeutic use, Ritonavir therapeutic use, Salvage Therapy
- Abstract
Purpose: To explore the possibility of overcoming resistance to protease inhibitors (PIs) and to determine the resistance cutoff values that continue to predict treatment failure with a dual PI regimen., Method: We performed a prospective study of 53 patients who had failed in several PIs and who were included in a ritonavir (RTV) plus indinavir (IDV) salvage regimen. Median HIV RNA level decrease was evaluated according to resistance assays and indinavir trough levels., Results: Eighty-seven percent of patients had previously failed on an IDV-containing regimen. Overall, median HIV RNA decrease was -1.25 log(10) copies/mL after 3 months on therapy. A significant blunted virologic response was observed only in isolates with more than 12 substitutions including the V82A (-0.75 vs. -1.3 log(10) copies/mL; p =.04), or in isolates with more than 30 fold-increase in the IC(50) (-0.43 vs. -1.2 log(10) copies/mL). Higher drug levels were observed in patients with resistant isolates who achieved an HIV RNA decrease greater than 1 log (1742 vs. 1100 ng/mL)., Conclusion: Our preliminary data suggest the possibility of overcoming resistance with the combination of RTV plus IDV. They also suggest the need for establishing new resistance cutoff values when using PIs in combination.
- Published
- 2003
- Full Text
- View/download PDF
3. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
- Author
-
Casado JL, Dronda F, Hertogs K, Sabido R, Antela A, Martí-Belda P, Dehertogh P, and Moreno S
- Subjects
- Adult, Aged, Drug Combinations, Drug Resistance, Microbial, Drug Therapy, Combination, Female, HIV enzymology, HIV genetics, HIV Infections virology, HIV Protease genetics, HIV Protease Inhibitors pharmacokinetics, Humans, Indinavir therapeutic use, Male, Middle Aged, Mutation, Nelfinavir pharmacokinetics, Nelfinavir therapeutic use, Prospective Studies, RNA, Viral blood, Ritonavir therapeutic use, Saquinavir pharmacokinetics, Saquinavir therapeutic use, Treatment Failure, Viral Load, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, HIV Protease Inhibitors therapeutic use, Nevirapine therapeutic use, Stavudine therapeutic use
- Abstract
The high rate of protease inhibitor treatment failure in clinical cohorts makes it necessary to define novel salvage therapies. In a prospective study of 31 HIV-infected patients included in a salvage regimen with stavudine, nevirapine, nelfinavir, and saquinavir, viral load decreased a median of 1.65 log(10) and 1.95 log(10) after 6 and 12 months of treatment, respectively, and 35 and 56% of patients had an HIV RNA level below 50 copies/ml at the same time points. At baseline, the mean number of mutations in the protease gene was 10 (2-19), and the V82A and L90M mutations were present in 54 and 21% of patients. The presence of the V82A mutation did not affect significantly the rate of response (36 vs. 38%), whereas the L90M mutation was associated with treatment failure (0 vs. 43%). Plasma trough levels of nelfinavir (NFV) and saquinavir (SQV), in a twice daily dosing regimen, were above the protein-corrected IC(95) in most patients despite the addition of an enzymatic inducer such as nevirapine, and peak levels were 2- and 5-fold increased with respect to standard doses. However, pharmacokinetics of saquinavir-hard gel capsule (SQV-hgc) did not improve significantly in the three times daily dosing regimen. In conclusion, the combination of stavudine, nevirapine, nelfinavir, and saquinavir increased plasma drug levels and produced an adequate virological response in patients who had failed indinavir or ritonavir therapy. This degree of response is not significantly decreased in the presence of genotypic mutations associated with indinavir/ritonavir (IDV/RTV) resistance.
- Published
- 2001
- Full Text
- View/download PDF
4. A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: influence of increased plasma drug levels in the rate of response.
- Author
-
Casado JL, Moreno A, Sabido R, Martí-Belda P, Antela A, Dronda F, Perez-Elías MJ, and Moreno S
- Subjects
- Anti-HIV Agents therapeutic use, Drug Therapy, Combination, HIV Infections virology, HIV Protease Inhibitors pharmacokinetics, Humans, Indinavir pharmacokinetics, Prospective Studies, Reverse Transcriptase Inhibitors therapeutic use, Ritonavir pharmacokinetics, Treatment Outcome, Viral Load, HIV Infections drug therapy, HIV Protease Inhibitors therapeutic use, HIV-1 drug effects, HIV-1 genetics, HIV-1 physiology, Indinavir therapeutic use, Ritonavir therapeutic use, Salvage Therapy
- Abstract
Purpose: The purpose of our study was to evaluate the efficacy of indinavir (IDV) in a twice daily dosing regimen with coadministration of 100 mg ritonavir (RTV) and to explore the influence of plasma drug levels in the rate of virologic response., Method: We performed a prospective study of 59 patients who switched to a salvage regimen with two nucleoside analogs plus the combination of 100 mg RTV plus 800 mg IDV twice daily. Pharmacokinetics of IDV and RTV were assessed in 11 patients., Results: Previous antiretroviral exposure was 44 months, and 78% and 39% of patients had previously failed regimens with either IDV or RTV. Median CD4 count was 248 x 10(6)/L and HIV load was 3.9 log(10) copies/mL. The median number of mutations in the protease gene was 9 (3-14), predominantly at residues 82 (53%), 90 (42%), and 46 (32%). After 24 weeks, 61% of patients had a viral load decrease greater than 1 log(10), and 38% had a viral load below 50 copies/mL. Nephrolitiasis, hematuria, or flank pain was observed in 13 patients (22%), leading to withdrawal in six cases (10%). IDV trough levels were well above the IC(95) (median 1.75 mg/L, interquartile range 1.07-2.57), but RTV trough levels were below the IC(95) in 88% of patients. There was a close correlation between higher peak levels of IDV, virological response, and renal toxicity., Conclusion: RTV/IDV 100/800 mg in a twice daily dosing regimen is associated with a significant virological response in patients with antiretroviral treatment failure. The correlation between plasma drug levels, toxicity, and response suggests the usefulness of individualized drug monitoring.
- Published
- 2000
- Full Text
- View/download PDF
5. Percentage of adherence correlates with the risk of protease inhibitor (PI) treatment failure in HIV-infected patients.
- Author
-
Casado JL, Sabido R, Perez-Elías MJ, Antela A, Oliva J, Dronda F, Mejía B, and Fortún J
- Subjects
- Adult, Aged, CD4 Lymphocyte Count, Female, HIV Infections immunology, HIV Infections virology, Humans, Male, Middle Aged, Prospective Studies, Treatment Failure, Viral Load, HIV Infections drug therapy, HIV Protease Inhibitors therapeutic use, Patient Compliance
- Abstract
Objectives: To determine the effect of adherence on the rate of protease inhibitor (PI) treatment failure among human immunodeficiency virus (HIV)-infected patients., Methods: A prospective study of a cohort of 282 patients who initiated PI therapy from March 1996 to December 1997. Adherence was quantified as the percentage of prescribed doses reportedly taken and treatment failure was defined as HIV RNA levels above 200 copies/ml after 1 year on therapy., Results: Overall, 190 patients (67%) missed prescribed doses. However, mean percentage of doses taken was 91% (range, 21-100%). Demographic, virological and immunological characteristics could not predict adherence outcomes. The causes of non-adherence included intolerance or side effects (35%), complexity of treatment (23%), or recurrence in active drug abuse (17%), whereas abandonment owing to HIV-related disease was uncommon (6%). A degree of adherence above 90% correlated significantly with viral suppression [relative risk (RR) 1.69; 95% confidence interval (CI) 1.1-2.56; P<0.01]. In a multivariate analysis, a lower degree of adherence (RR, 0.96; P=0.006), a higher HIV viral load (RR, 2.03; P=0.0001), prior antiretroviral therapy (RR, 2.5; P=0.01), and use of saquinavir-hard gel capsules (saquinavir-HGC) (RR, 1.77; P=0.03) were strongly associated with treatment failure., Conclusion: The percentage of adherence and initial HIV viral load are the most important determinants of virological response to PI therapy and non-adherence is related to treatment-related factors in the majority of cases.
- Published
- 1999
6. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients.
- Author
-
Casado JL, Perez-Elías MJ, Antela A, Sabido R, Martí-Belda P, Dronda F, Blazquez J, and Quereda C
- Subjects
- Adult, Aged, CD4 Lymphocyte Count, Cohort Studies, Female, HIV Infections immunology, HIV Infections virology, Humans, Male, Middle Aged, Predictive Value of Tests, Prospective Studies, RNA, Viral blood, Time Factors, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, HIV Protease Inhibitors therapeutic use, HIV-1 genetics, Indinavir therapeutic use, Ritonavir therapeutic use, Saquinavir therapeutic use
- Abstract
Objective: To assess the rate of long-term effectiveness and factors associated with response to protease inhibitor therapy in a cohort of HIV-infected patients., Design and Setting: Prospective, non-randomized study in a tertiary care centre., Patients: A total of 400 HIV-infected patients who started on protease inhibitor therapy (saquinavir, 28%; ritonavir, 26%; indinavir, 46%) from March 1996 to March 1997., Main Outcomes Measures: Long-term virological and immunological effectiveness were defined as HIV RNA levels below 200 copies/ml and CD4+ cell count increase greater than 100 x 10(6)/l, respectively, after 12 months of therapy., Results: Fifty-seven per cent of patients had a prior AIDS-defining illness, and 91% had received nucleoside analogues for a median time of 28 months. Median CD4+ count was 86 x 10(6) cells/l and HIV RNA level was 4.46 log10 copies/ml. The global rate of virological and immunological effectiveness at 1 year was 45 and 59%, respectively. In a logistic regression analysis, treatment failure was associated with higher baseline HIV load [relative risk (RR), 2.10; P<0.01], prior antiretroviral therapy (RR, 2.07; P<0.01), and use of saquinavir (RR, 1.55; P = 0.03), whereas a reduction of more than 1 log10 in HIV load within the first 3 months on therapy was strongly associated with response (RR, 0.65; P<0.01). There was no strict correlation between virological and immunological effectiveness (r = -0.35; P = 0.01)., Conclusions: Nearly half of the patients maintain undetectable HIV load after 1 year of therapy, although important immunological benefit can be obtained in a greater proportion of patients. These data suggest the use of the most potent antiretroviral therapy in pretreated patients with high HIV load, and the capacity of initial virological decline to predict the long-term outcome.
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.